Edit

Terns Pharmaceuticals

https://www.ternspharma.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tab

Last activity: 10.09.2024

Active

Categories: DevelopmentDrugLifeMedtech

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single- agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.

Followers

120

Mentions

Location: United States, California, Foster City

Employees: 11-50

Total raised: $177.7M

Founded date: 2017

Twitter

Investors 3

Date	Name	Website
-	LAV	lavfund.co...
-	OrbiMed	orbimed.co...
-	Vivo Capit...	vivocapita...

Funding Rounds 2

Date	Series	Amount	Investors
05.01.2021	Series C	$97.7M	-
30.10.2018	Series B	$80M	-

Mentions in press and media 23

Date	Title	Description
10.09.2024	Terns Announces Pricing of Upsized $150.15 Million Public Offering	FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address...
10.09.2024	Дешевле, эффективнее и без уколов. Новый «Оземпик» на подходе	Кажется, что человечество стало еще на шаг ближе к исполнению «ленивых желаний». Никаких тренировок, никакой диеты – закинул таблетку и почти безвредно похудел. И если препарат Оземпик стоил дорого и вводился иглой, то теперь на рынке новый...
05.08.2024	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates	Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemi...
11.03.2024	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia	FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address...
11.03.2024	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia	-
07.03.2024	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)	-
21.12.2022	Terns Announces Pricing of $75 Million Public Offering	FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates t...
20.12.2022	Terns Announces Pricing of $75 Million Public Offering	-
12.08.2022	Terns Announces $65 Million Oversubscribed Offering	FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address ...
28.02.2021	3 New IPOs Trending Higher Heading Into March	February was an active month for IPOs.
07.01.2021	Terns Pharmaceuticals, Inc. announced that it has received $97.703068 million in funding from a group of investors	On January 7, 2021, Terns Pharmaceuticals, Inc. closed the transaction. The company has received $10,703,068 in its second and final tranche from 18 investors. The company has raised $97,703,068 in the transaction.
06.01.2021	Terns Pharmaceuticals Raises $87M in Series C	FOSTER CITY, CA, Terns Pharmaceuticals has closed an $87 million Series C financing led by Deerfield Management Company. >> Click here for more funding data on Terns Pharmaceuticals >> To export Terns Pharmaceuticals funding...
05.01.2021	Terns raises $87M to advance trials of NASH drugs	Terns said it will use the proceeds of its series C round to advance clinical trials of its three NASH candidates. The furthest along is TERN-101, a liver-directed non-bile acid farnesoid X receptor (FXR) agonist. Terns currently has 96 pat...
05.01.2021	Lilly-backed Terns raises $87M for multi-front assault on NASH W h i t e p a p e r Weighing the Costs:	Terns Pharmaceuticals has raised $87 million to fund clinical trials of its three lead nonalcoholic steatohepatitis (NASH) candidates. Deerfield Management led the round with assists from investors including Eli Lilly. Sponsored by Agilent ...
05.01.2021	TERNS CLOSES $87 MILLION SERIES C FINANCING TO ADVANCE NASH PORTFOLIO	-
05.01.2021	Lilly-backed Terns raises $87M for multi-front assault on NASH	Terns Pharmaceuticals has raised $87 million to fund clinical trials of its three lead nonalcoholic steatohepatitis (NASH) candidates. Deerfield Management led the round with assists from investors including Eli Lilly. Stumbles by Intercept...
30.10.2018	Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs	The company – which is based in San Mateo, California, and Shanghai – said it plans to use the money to develop its two lead drug candidates, TERN-101 and TERN-201, which it expects to enter into the clinic in the first half of next year. B...
30.10.2018	Terns scores $80M in Series B financing led by Vivo, OrbiMed	Weidong Zhong Transpacific biotech upstart Terns Pharmaceuticals, which is focused on developing treatments for NASH and cancer, has closed $80 million in Series B financing as it prepares to shepherd its lead experim...
30.10.2018	Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer	-
04.04.2018	Terns emerges with all 3 of Lilly’s NASH programs and $30M from Lilly Asia Ventures	The hot nonalcoholic steatohepatitis (NASH) arena has a new player, Terns Pharmaceuticals, and it has already got three programs from Eli Lilly and a $30 million series A backed by Lilly Asia Ventures. Announced a week before the EASL liver...
-	Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs	A company focused on cancers and advanced fatty liver disease has completed its latest round of venture capital financing. Terns Pharmaceuticals said Tuesday that it had closed an $80 million Series B funding round, led by Vivo Capital and ...
-	Terns raises $87M to advance trials of NASH drugs	After gaining a big backer in Eli Lilly & Co. two years ago, Terns Pharmaceuticals now has two NASH candidates in clinical trials. The startup, headquartered in Foster City, Calif., recently raised $87 million to push forward in a compe...
-	The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space	Drugmakers have been scrambling to join a two-horse race to make highly sought after weight loss drugs. There may still be room for lesser-known competitors like the privately held Boehringer Ingelheim, and smaller public companies such as ...

Terns Pharmaceuticals

Investors 3

Funding Rounds 2

Mentions in press and media 23

Reviews 0